|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Yamaoka Y, Kato M and Asaka M: Geographic
differences in gastric cancer incidence can be explained by
differences between Helicobacter pylori strains. Intern Med.
47:1077–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Center MM, Jemal A and Ward E:
International trends in colorectal cancer incidence rates. Cancer
Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Legge F, Fuoco G, Lorusso D, et al:
Pharmacotherapy of cervical cancer. Expert Opin Pharmacother.
11:2059–2075. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkin DM: International variation.
Oncogene. 23:6329–6340. 2004. View Article : Google Scholar
|
|
6
|
Schiff D, Wen PY and van den Bent MJ:
Neurological adverse effects caused by cytotoxic and targeted
therapies. Nat Rev Clin Oncol. 6:596–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaushal GP, Kaushal V, Herzog C and Yang
C: Autophagy delays apoptosis in renal tubular epithelial cells in
cisplatin cytotoxicty. Autophagy. 4:710–712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee S, Kim W, Moon SO, et al:
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Nephrol Dial Transplant. 21:2096–2105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao X, Panichpisal K, Kurtzman N and
Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci.
334:115–124. 2007. View Article : Google Scholar
|
|
10
|
Zhang HZ, Liu JG, Wei YP, et al:
Expression of G3BP and RhoC in esophageal squamous carcinoma and
their effect on prognosis. World J Gastroenterol. 13:4126–4130.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ning JY, You JF, Pei F, et al: Monoclonal
antibody against G3BP: preparation, characterization and its
application in analysis of human tumors. Zhonghua Bing Li Xue Za
Zhi. 34:215–219. 2005.(In Chinese).
|
|
12
|
Cui W, Wei Z, Chen Q, et al:
Structure-based design of peptides against G3BP with cytotoxicity
on tumor cells. J Chem Inf Model. 50:380–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JH, Huang YU, Xiong YU and Chen CH:
Peptides or derivatives which treat or prevent cancers and the
application CN Patent 200910163852. Issued August 11, 2009.
|
|
14
|
Zhang J, Tan SY, Chen JH, et al:
Polypeptide A28 enhances cytotoxic effect of cisplatin on colon
cancer cell line HCT-116. Chin J Cancer Biother. 17:318–321.
2010.(In Chinese).
|
|
15
|
Kaufmann SH, Peereboom D, Buckwalter CA,
et al: Cytotoxic effects of topotecan combined with various
anticancer agents in human cancer cell lines. J Natl Cancer Inst.
88:734–741. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan and cisplatin against human teratocarcinoma cell growth:
a rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guitard E, Parker F, Millon R, et al: G3BP
is overexpressed in human tumors and promotes S phase entry. Cancer
Lett. 162:213–221. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Zheng J, Fang W, et al:
Identification of metastasis associated gene G3BP by differential
display in human cancer cell sublines with different metastatic
potentials G3BP as highly expressed in non-metastatic. Chin Med J
(Engl). 114:35–38. 2001.PubMed/NCBI
|
|
19
|
French J, Stirling R, Walsh M and Kennedy
HD: The expression of Ras-GTPase activating protein SH3
domain-binding proteins, G3BPs, in human breast cancers. Histochem
J. 34:223–231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barnes CJ, Li F, Mandal M, et al:
Heregulin induces expression, ATPase activity and nuclear
localization of G3BP, a Ras signaling component, in human breast
tumors. Cancer Res. 62:1251–1255. 2002.PubMed/NCBI
|
|
21
|
Parker F, Kenigsberg M, Duchesne M, et al:
Monoclonal antibodies directed against the G3BP protein and uses US
Patent 7001980B1 [P]. Issued February 21, 2006.
|
|
22
|
Parker F, Maurier F, Delumeau I, et al: A
Ras-GTPase-activating protein SH3-domain-binding protein. Mol Cell
Biol. 16:2561–2569. 1996.PubMed/NCBI
|
|
23
|
Kennedy D, French J, Guitard E, et al:
Characterization of G3BPs: tissue specific expression, chromosomal
localisation and rasGAP(120) binding studies. J Cell Biochem.
84:173–187. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen M and Wang J: Initiator caspases in
apoptosis signaling pathways. Apoptosis. 7:313–319. 2002.
View Article : Google Scholar
|
|
27
|
Green DR: Apoptotic pathways: ten minutes
to dead. Cell. 121:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Michod D, Yang JY, Chen J, et al: A
RasGAP-derived cell permeable peptide potently enhances
genotoxin-induced cytotoxicity in tumor cells. Oncogene.
23:8971–8978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Zhang S, He H, et al:
RasGAP-derived peptide 38GAP potentiates the cytotoxicity of
cisplatin through inhibitions of Akt, ERK and NF-κB in colon
carcinoma HCT116 cells. Cancer Lett. 308:62–70. 2011.PubMed/NCBI
|
